Nkarta, Inc.

NKTX
About the company

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis.

Country: United StatesPrice: $1.19Market Cap: $85.2M

Investment snapshot

0%positive consensus
Scored 1d ago

Positive

0

BUY / PASS

Neutral / negative

2 / 14

NEUTRAL / FAIL

Median fair value

—

No comparable estimates

Models with upside

0 / 17

Positive margin of safety

Key risk

No clean pass — all 13 investors flag at least one valuation criterion

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictFAILFAILFAILFAIL · Rank #2728 (Top 88.1%)FAILFAILFAILFAILFAILFAILFAILFAILFAILNEUTRALFAILFAILNEUTRAL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Margin of SafetyN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Financial Basis

Annual history · FY 2025 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-25

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-25

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-25

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-03-25

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-03-25

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-03-25

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-03-25

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Market data at 2026-11-01

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-03-25

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-03-25

Score computed: 2026-11-14

TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2025

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Where It Passes

    Where It Falls Short

    • Valuation0% pass✓ 8✗ 20▾

      No clean pass — all 13 investors flag at least one valuation criterion

      Price / 3-yr avg EPS
      ✗Graham<= 15x
      Price-to-Book Ratio0.3x
      ✓Graham<= 1.5x
      P/E x P/B
      ✗Graham<= 22.5
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      EBIT / Enterprise Value-267.5%
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=-267.5%, ROC=-42.5%
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Price / EPS
      ✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
      Price / (CFO / Shares)N/A (negative CFPS)
      ✗Dreman< 8x
      Price / Book Value per Share0.3x
      ✓Dreman< 1.2x✓Templeton< 1.5x✓SchlossP/B <= 0.80x (app cutoff)
      Valuation ReasonablenessOE Yield=-113.3%
      ✗MungerP/E < 25 or Owner Earnings Yield > 5%
      P/E or FCF YieldFCF Yield=-105.5%
      ✗PabraiP/E < 15 or FCF Yield > 10%
      P/B or P/E vs. Historical AverageP/B=0.3x
      ✓MarksP/E < 15 or P/B < 2.0
      Discount to Intrinsic Value
      ✗Marks>= 20% below intrinsic value
      Price / FCF per ShareN/A (negative FCF)
      ✗Ackman<= 25
      Price vs. Trailing Low100% of trailing low ($1.19)
      ✓Templeton<= 120% of trailing low (certified split-adjusted live window)
      Net income / market capitalization-151.27%; #5575/6340 (top 87.9%)
      ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
      Positive book equity / market capitalization+2.5313; #541/6449 (top 8.4%)
      ✓AsnessTop 30% of eligible cross-section
      Price / Diluted EPS
      ✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
      (EPS CAGR % + Dividend Yield %) / P/E
      ✗Neff> 0.7 (Neff's published traditional edge)
      Price / Tangible Book Value per Share0.27x
      ✓SchlossP/TBV <= 1.00x (app cutoff)
      Book Value per Share Change
      ✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
      Revenue / market capitalization+0.0000; #5080/5247 (top 96.8%)
      ✗OshaughnessyTop 10% of eligible cross-section
      (Operating cash flow - capex) / market capitalization-120.03%; #4103/4519 (top 90.8%)
      ✗OshaughnessyTop 10% of eligible cross-section
      Trailing six-month price return through the evaluation date-45.16%; #4989/6202 (top 80.4%)
      ✗OshaughnessyTop 10% of eligible cross-section
    • Cash Flow0% pass✓ 1✗ 11▾

      No clean pass — all 10 investors flag at least one cash flow criterion

      Free Cash Flow Proxy$-96.1M
      ✗BuffettPositive and growing
      FCF Positive and Growing$-89.9M
      ✗LynchPositive and growing
      Operating Cash Flow$-88.7M
      ✗PiotroskiCFO > 0
      (CFO / Total Assets) vs ROACFO/Assets=-21.94%, ROA=-25.75%
      ✓PiotroskiCFO/Assets > ROA
      Price / (CFO / Shares)N/A (negative CFPS)
      ✗Dreman< 8x
      P/E or FCF YieldFCF Yield=-105.5%
      ✗PabraiP/E < 15 or FCF Yield > 10%
      FCF Positive0/7 years FCF positive
      ✗MarksPositive FCF in majority of recent years
      (OCF - CapEx) / Market Cap-120.6%
      ✗Ackman>= 4%
      Price / FCF per ShareN/A (negative FCF)
      ✗Ackman<= 25
      Positive Operating Cash Flow frequency0/7 years positive
      ✗SleepPositive OCF in >= 70% of available years
      Operating Cash Flow - Capital Expenditures$-102.3M
      ✗Neff> $0 (app proxy for a strong fundamental case)
      (Operating cash flow - capex) / market capitalization-120.03%; #4103/4519 (top 90.8%)
      ✗OshaughnessyTop 10% of eligible cross-section
    • Growth0% pass✓ 1✗ 12▾

      No clean pass — all 8 investors flag at least one growth criterion

      EPS Growth (3-yr avg, 10-yr window)
      ✗Graham>= 33% growth
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      Inventory Growth vs Revenue GrowthN/A (no inventory)
      ✓LynchInventory growth < Revenue growth
      EPS Growth Direction
      ✗DremanPositive over recent years
      EPS CAGR
      ✗Dreman> 5% annualized
      Positive Net Income Frequency0/7 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      3yr Median Revenue Growth
      ✗Ackman>= 5%
      Positive EPS Growth Frequency
      ✗AckmanPositive EPS growth in >= 3 of last 5 years
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Revenue growth vs. gross and operating margin trend
      ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
      5-year Revenue CAGR
      ✗SleepCAGR > 7%
      3-5 Year Diluted EPS CAGR
      ✗Neff7%-20% annualized
    • Verdicts0% pass✗ 15▾

      Split decision: 14 FAIL · 2 NEUTRAL

      Overall verdict
      ✗GrahamFAIL (2/9)✗BuffettFAIL (0/9)✗LynchFAIL (1/7)✗GreenblattRank #2728✗PiotroskiFAIL (F-Score 2)✗DremanFAIL (2/11)✗MungerFAIL (0/4)✗PabraiFAIL (1/3)✗AkreFAIL (0/6)✗MarksFAIL (1/5)✗AckmanFAIL (0/9)✗TempletonFAIL (3/8)✗SleepFAIL (1/6)•AsnessNEUTRAL (Not ranked)✗NeffFAIL (0/6)✗SchlossFAIL (3/7)•OshaughnessyNEUTRAL (Not ranked)
    • Profitability6% pass✓ 2✗ 33▾

      15 of 16 flag NKTX's profitability — Graham, Buffett, Lynch +12 more

      Positive EPS (10 years)0/8 years positive
      ✗GrahamPositive EPS every year for 10 years
      EPS Growth (3-yr avg, 10-yr window)
      ✗Graham>= 33% growth
      Net Income Positive (10+ years)0/8 years positive
      ✗BuffettPositive every year for 10+ years
      ROE (up to 5-year arithmetic mean)-33.6%
      ✗Buffett> 15% arithmetic mean (app rule)
      Operating Margin (10-yr trend)
      ✗BuffettStable or rising over 10 years
      Free Cash Flow Proxy$-96.1M
      ✗BuffettPositive and growing
      Earnings Variance (10-yr CoV)
      ✗BuffettCoV < 0.3
      Retained Earnings Effectiveness
      ✗Buffett$1 retained -> > $1 market value created
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      ROE-59.8%
      ✗Lynch> 15%
      EBIT / Enterprise Value-267.5%
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=-267.5%, ROC=-42.5%
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Net Income / Total Assets-25.75%
      ✗PiotroskiROA > 0
      ROA Change YoY-21.71% -> -25.75% (delta: -4.04%)
      ✗PiotroskiCurrent ROA > Prior ROA
      (CFO / Total Assets) vs ROACFO/Assets=-21.94%, ROA=-25.75%
      ✓PiotroskiCFO/Assets > ROA
      Gross Margin Change YoY
      ✗PiotroskiImproved YoY
      Pre-Tax Income / Revenue
      ✗Dreman>= 8%
      Net Income / Shareholders' Equity-59.8%
      ✗Dreman> 12%
      Margin of SafetyP/B=0.3x
      ✓PabraiP/B < 1.5 or P/E < 15
      Return on Equity-34.3% (3-yr avg)
      ✗AkreROE > 20% (3-year avg)
      Discount to Intrinsic Value
      ✗Marks>= 20% below intrinsic value
      Positive Net Income Frequency0/7 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      Operating Income / Revenue
      ✗Ackman>= 15%
      Net Income / Shareholders Equity-59.8%
      ✗Ackman>= 15%
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Operating Margin Trend
      ✗TempletonNon-negative operating-margin trend over 3 years
      Revenue growth vs. gross and operating margin trend
      ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
      Net income / market capitalization-151.27%; #5575/6340 (top 87.9%)
      ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
      Gross profit / total assets
      ✗AsnessTop 30% of eligible cross-section
      Net income / positive book equity-59.76%; #4314/5226 (top 82.5%)
      ✗AsnessTop 30% of eligible cross-section
      Negative 5-year standard deviation of ROA-0.0384; #2230/5884 (top 37.9%)
      ✗AsnessTop 30% of eligible cross-section
      3-5 Year Diluted EPS CAGR
      ✗Neff7%-20% annualized
      Positive Diluted-EPS Years0/7 years positive
      ✗Schloss>= 70% positive over 5-10 observed years (app rule)
    • Debt & Leverage8% pass✓ 3✗ 12▾

      11 of 12 flag NKTX's debt & leverage — Graham, Buffett, Lynch +8 more

      LT Debt vs Net Current Assets
      ✗GrahamLT Debt <= Net Current Assets
      Debt/Equity & Interest Coverage
      ✗BuffettD/E < 0.5 AND Interest Coverage > 5x
      Total Debt / Equity
      ✗Lynch< 0.33
      Cash - Long-term Debt
      ✗LynchPositive preferred
      LT Debt / Total Assets Change0.00% -> 0.00%
      ✓PiotroskiDecreased YoY
      Current Assets / Current Liabilities5.79
      ✓Dreman> 1.5✓SchlossCurrent ratio >= 1.50x (app cutoff)
      Total Debt / Shareholders' Equity
      ✗Dreman< 0.8✗Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✗SchlossD/E < 1.00x
      Debt Levels
      ✗MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3
      Interest Coverage & Debt/EBITDA
      ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
      Total Debt / Shareholders Equity
      ✗Ackman<= 1.0
      Negative debt-to-equity (higher means less debt)
      ✗AsnessTop 30% of eligible cross-section
    • Efficiency25% pass✓ 2✗ 9▾

      6 of 8 flag NKTX's efficiency — Buffett, Greenblatt, Piotroski +3 more

      Current Ratio5.79
      ✓Graham>= 2.0
      ROIC (3-5 yr avg)
      ✗Buffett> 10%
      ROIC - WACC
      ✗BuffettPositive (WACC = 10%)
      EBIT / (NWC + Net Fixed Assets)-42.5%
      ✗Greenblatt> 25%
      Current Ratio Change YoY14.45 -> 12.69
      ✗PiotroskiIncreased YoY
      Revenue / Total Assets Change YoY0.00x -> 0.00x
      ✗PiotroskiImproved YoY
      Current Assets / Current Liabilities5.79
      ✓Dreman> 1.5
      Return on Invested Capital
      ✗Munger> 15%
      ROIC (high and growing)FY2023: ROIC=unavailable; FY2024: ROIC=unavailable; FY2025: ROIC=unavailable
      ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
      Reinvestment Rate x ROIC
      ✗AkreReinvestment Rate * ROIC > 10%
      ROIC (5-year)
      ✗SleepROIC > 12% in a majority of years

    Business & financials

    Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.

    Company Profile

    Industry: Pharmaceutical Products
    SIC Sector: Chemicals & Pharmaceuticals
    Size: Micro Cap($85.2M)
    Revenue: $0.00
    Net Income: $104.1M+4.3% YoY

    Financial Snapshot

    Operating Margin--
    Return on Equity-33.3%
    Debt / Equity--
    Current Ratio12.69
    EPS (Diluted)$-1.41
    Shares Retired−0.5%

    Shareholder Return

    Fiscal 2025

    Issued 0.5% of shares last year.

    Buybacks
    —
    Dividends
    —

    Company Financials

    Latest TTM and quarters alongside annual years

    TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

    The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.

    MetricTTM · 2026-09-30

    2025-10-01 – 2026-09-30

    Sources · derived quarter values

    Derived from cumulative filings: net income, operating income, ebit, operating cash flow, depreciation amortization, capex.

    Q3 FY 2026

    2026-07-01 – 2026-09-30

    Sources · derived quarter values

    Derived from cumulative filings: operating cash flow, capex.

    Q2 FY 2026

    2026-04-01 – 2026-06-30

    Sources · derived quarter values

    Derived from cumulative filings: operating cash flow, capex.

    Q1 FY 2026

    2026-01-01 – 2026-03-31

    Sources
    FY 2025
    Sources
    • 10-K · 2026-03-25
    FY 2024
    Sources
    • 10-K · 2025-03-26
    FY 2023
    Sources
    • 10-K · 2024-03-21
    FY 2022
    Sources
    • 10-K · 2023-03-16
    FY 2021
    Sources
    • 10-K · 2022-03-17
    Market Cap$85.2Mcurrent------$158.3Mest.$166.0Mest.$446.7Mest.$260.8Mest.$327.0Mest.
    Revenue--------$0$0------
    Operating Income-$140.7M↓15%-$35.8M↓31%-$43.1M↓59%-$30.9M↑16%-$122.0M↑5%-$128.2M↑3%-$131.7M↓11%-$119.0M↓38%-$86.4M
    Net Income-$128.9M↓26%-$33.3M↓53%-$40.4M↓76%-$27.8M↑13%-$104.1M↑4%-$108.8M↑7%-$117.5M↓3%-$113.8M↓32%-$86.1M
    EPS (Diluted)--$-0.45↓55%$-0.54↓74%$-0.37↑14%$-1.41↑12%$-1.60↑33%$-2.40↑8%$-2.61$-2.62
    Gross Margin—————————
    Operating Margin—————————
    ROE-59.8%↓97%———-33.3%↓25%-26.7%↑38%-43.0%↓41%-30.6%↑11%-34.3%
    Total Debt------------------
    Shareholders' Equity$215.7M↓36%$215.7M↓36%$247.7M↓31%$285.9M↓25%$312.3M↓23%$408.0M↑49%$273.3M↓27%$372.2M↑48%$251.0M
    Current Ratio5.79↓62%5.79↓62%7.98↓49%12.96↓11%12.69↓12%14.45↑33%10.85↓34%16.36↓14%18.99
    Debt / Equity—————————
    Operating Cash Flow-$99.9M↓9%-$25.8M↓38%-$24.2M↓29%-$28.2M↑5%-$88.7M↑11%-$99.7M↓16%-$86.2M↓51%-$57.0M↑16%-$67.9M
    Free Cash Flow-$102.3M-$27.1M-$24.4M↓29%-$28.6M↑5%-$89.9M↑14%-$104.1M↑9%-$114.3M↓10%-$104.1M↓43%-$73.0M

    Score history

    Historical Score Timeline

    Industry peers

    Industry Peers

    Similar companies in Pharmaceutical Products

    NKTX vs Peers — Financial Grading

    Revenue$0.00Bottom 25%
    Net Income$104.1MBottom 25%
    ROE-33.3%Bottom 25%
    D/E—
    Op. Margin—
    Curr. Ratio12.69Top 25%
    CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
    Merck & Co., Inc.MRK$364.3B$147.76$65.0B$18.3B34.7%0.94—1.542/95/94/70/3F-Score 41/11
    ABBOTT LABORATORIESABT$188.0B$108.52$44.3B$6.5B12.5%0.2518.2%1.583/94/92/71/3F-Score 53/11
    BRISTOL MYERS SQUIBB COBMY$129.7B$63.43$48.2B$7.1B38.2%2.4419.4%1.262/91/93/71/3F-Score 85/11
    BIO-TECHNE CorpTECH$11.4B$72.80$1.2B$73.4M3.8%—8.4%3.464/93/93/70/3F-Score 54/11
    REPLIGEN CORPRGEN$10.7B$167.79$738.3M$48.9M2.3%0.267.5%8.373/92/93/70/3F-Score 75/11
    IONIS PHARMACEUTICALS INCIONS$4.8B$29.06$943.7M$381.4M-78.0%3.60-40.4%3.833/91/91/70/3F-Score 43/11
    NEOGEN CORPNEOG$2.5B$11.23$870.4M$7.9M-0.4%0.76-2.5%3.823/91/92/70/3F-Score 64/11
    Pharvaris N.V.PHVS$2.4B$33.36—$206.4M-64.8%0.00——0/90/92/70/3F-Score 22/11